<unk>  is a drug under development for the treatment of peripheral neuropathic pain. Trials were discontinued in 2015, with new trials scheduled to begin March, 2018. It was initially established as a potential drug option for patients suffering pain caused by postherpetic neuralgia. It may also be useful for treating various types of chronic neuropathic pain<unk>  has shown efficacy in preclinical models of shingles, diabetes, osteoarthritis, HIV and chemotherapy.<unk>  is a competitive antagonist of angiotensin II type 2 receptor (ATR) being developed by the Australian biotechnology company Spinifex Pharmaceuticals.<unk>  target angiotensin II type 2 receptors, which may have importance for painful sensitisation.
EMA401
MRK-016
AEMT-CC
OSU-6162
ICE 
HAMLET 
ZF2001
DEBRA